“Pharmacy practice in the domain of assisted dying: A mapping review of the literature”

Revised Manuscript: RSAP_2018_621_R1

Authors:

Phillip Woods, School of Pharmacy and Pharmacology, Griffith University, Australia.

Email: Phillip.Woods@griffith.edu.au

Theresa J. Schindel, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada. Email: terri.schindel@ualberta.ca

Michelle A. King, Menzies Health Institute Queensland, School of Pharmacy and Pharmacology, Griffith University, Australia. Email: Michelle.A.King@griffith.edu.au

Amary Mey, Menzies Health Institute Queensland, Griffith Institute for the Development of Education and Scholarship (Health IDEAS), School of Pharmacy and Pharmacology, Griffith University, Australia. Email: a.mey@griffith.edu.au

Corresponding Author:

Phillip Woods PhD. School of Pharmacy and Pharmacology, Building G16, Room 4.21, Griffith University, Gold Coast campus, Queensland, 4222, Australia; Telephone: +61 7 55528312. Facsimile: +61 7 55528804.

Email: Phillip.Woods@griffith.edu.au

Pharmacy practice in the domain of assisted dying: A mapping review of the literature

ABSTRACT

Background

The scope and roles of pharmacists worldwide are undergoing dramatic change. Patient-focused care aimed at caring for people that seek medical assistance in dying is among the newest roles. While pharmacists have been involved in medically assisted dying in some international jurisdictions for over two decades, little is known about their actual lived experiences.

Objective

To map the literature concerning pharmacy practice in the assisted dying domain to clarify apparent research gaps.

Methods

A mapping review was preformed following a systematic search of Medline, CINAHL and IPA to locate academic papers and reports relating to pharmacists' involvement in assisted dying published between 1990 and 2019. Searches included articles in English, French, and Dutch. References and citations of articles were searched to identify additional articles.

Results

A total of 43 articles were selected, including commentaries (n=26), reports (n=2), a scoping literature review (n=1), and empirical studies (n=14). Most commentaries centered on pharmacists' roles, ethico-legal and moral challenges, and educational concerns in relation to participation. Of the 14 empirical studies, 12 studies were designed around surveys that focused on pharmacists' attitudes, and opinions concerning assisted dying. Other methodologies included thematic analysis of moral dilemmas, experimental design identifying attitudes to sedation at end of life, and analysis of documents such as guidelines, position statements, and standards of practice.

28 Two studies utilized a qualitative research approach. A significant gap was found with
29 respect to research exploring the actual experience of pharmacists' practice in medically
30 assisted dying.

31 Conclusion

32 There is an absence of studies exploring pharmacists' actual experiences in assisted
33 dying practice. Research involving pharmacists that participate in legally sanctioned
34 assisted dying will facilitate a meaningful understanding of the lived experience of
35 pharmacy practice in this domain.

36 Keywords

37 Pharmacy; medical assistance in dying; assisted dying; aid in dying; suicide, assisted;
38 euthanasia; mapping review.

Introduction

Over the past several years, health care policy in many developed nations has been changing and evolving.¹ The scope and roles of practice for health practitioners, including pharmacists, has also been changing and developing rapidly.²⁻⁵ Practicing patient-focused care aimed at lawfully assisting individuals to accomplish their own death has expanded to include a number of international jurisdictions.⁶ Different terminology is used to describe this practice, including medical assistance in dying (MAiD), physician assisted suicide (PAS) and voluntary assisted dying (VAD). These terms are defined and discussed by Varadarajan et al. 2016.⁶

Recently, the Australian State of Victoria passed the Voluntary Assisted Dying (VAD) Bill 2017, for commencement on June 19 2019⁷, making it the newest jurisdiction to legally allow assisted death. In doing so, Victoria joins Belgium, Canada, Colombia, Luxembourg, the Netherlands and the States of California, Colorado, Oregon, Vermont and Washington, and the District of Columbia in the United States of America, all of which have introduced laws permitting some form of assisted death.⁸ Switzerland, while not having explicit legislation surrounding assisted death, permits suicide assistance in circumstances not driven by “selfish motives”.^{9,10} The Swiss model is also not orchestrated as an entirely medical issue, allowing for key roles to be undertaken by non-physicians.¹¹

The increasing trend to legally legitimize some form of assisted dying appears to reflect the evolution of social norms from those of prohibition to a more permissive stance.¹² Some have pointed to an observable change in Western societies with aging populations, toward increasing secularism, individual autonomy and a demand for personal control.⁸ It is suggested that these factors, among others, may act as drivers toward greater permissiveness.¹³ Regardless of the societal drivers, health care practice that incorporates participation in assisting patients to achieve their own death, presents

challenges and new considerations for all professionals who do not recuse themselves due to conscientious objection. As reviewed by Fujioka, Mirza, McDonald and Klinger¹⁴, aspects of practice in the domain of assisted dying may include: consulting/supporting patients and other staff members with requests, assessing eligibility, administering/dispensing the lethal drugs, providing aftercare to bereaved relatives, and regulatory oversight.

The Victorian legislative development process has been guided by reviews of assisted dying laws from a range of developed nations.¹⁵ The resultant Victorian statute⁷ and its accompanying regulations¹⁶ provide a comprehensive description of criteria, minimum procedural requirements, necessary permits and rules, and procedures governing prescribing, dispensing and disposing of VAD substances. While the legal contexts and procedures are quite thoroughly covered, such documents understandably cannot illuminate how health practitioners will experience the fine-grained implementation of the procedures, with their dying patients and those that care-for and love them, over time.

The Pharmaceutical Society of Australia (PSA) acknowledges that pharmacists will have a crucial role in the VAD processes when the Victorian legislation is implemented in 2019.¹⁷ At the time of writing of this article, pharmacist representatives are involved in a range of VAD implementation taskforce projects, including the drafting of the Regulations to support the statute.^{18,19} As Australian pharmacists try to come to grips with the idea of assisting patients that seek their own death, some may find professional involvement incompatible with their philosophy of healthcare.¹⁷ Some will not feel this incompatibility and will agree to participate in the necessary practices strictly according to the law, its regulations and professional guidelines. For these pharmacists, and for those that are still in active contemplation, the informed

experiences of pharmacists that are already *actually* practicing in this area in international jurisdictions may prove to be very helpful.

Pharmacists have been involved in medically assisted dying in some international jurisdictions since the early 2000's, (e.g. Netherlands). Other jurisdictions have only recently implemented assisted dying laws (e.g. Canada, 2016). In Victoria, VAD will commence in June 2019.⁷ The laws and regulations are no longer theoretical and the general procedures that pharmacists must follow are known. Consequently, the Australian pharmacy profession is currently experiencing a period of tense anticipation. Perhaps pharmacists are now less concerned with the question "What will I have to do?", and more with the question "How will I experience this practice if I do it?".

The aim of this research was to clarify an apparent research gap concerning the experience of pharmacy practice in the domain of assisted dying by undertaking a mapping review of the literature.²⁰ The mapping review methodology²⁰ has been used as a means to characterize extant studies according to their theoretical perspective by observation of study design, identifying gaps in the knowledge base and to provide a transparent and organized summary of literature from which further research decisions can be made. The mapping review is presented as the preparative phase for a planned multi-phase international study involving pharmacists that participate in legally sanctioned assisted dying processes. Subsequent research phases are described later in this paper under the heading of 'Future Research'.

To begin, the Australian context and Victoria's approach to the planned implementation of VAD is briefly explained. Then a description of the mapping review method and analysis of the international literature pertaining to pharmacists' involvement in assisted dying practices are presented.

Voluntary Assisted Death (VAD): Australia

As in other international jurisdictions, Australian society is demanding to have control over the decision to end life in particular circumstances, and to have regulated professional assistance to carry out such a decision.²¹ In 2017, legislation in four Australian states was introduced into their respective parliaments regarding assisted dying law and regulation. The state parliament of Victoria passed the Voluntary Assisted Dying (VAD) Bill 2017, on November 29, 2017, for commencement on June 19, 2019.⁷ The state parliaments of New South Wales (NSW), South Australia (SA) and Tasmania narrowly rejected similarly structured bills. It is anticipated however, that the bills are likely to be reintroduced to those state parliaments in the near future.²²⁻²⁴ The remaining populous eastern Australian state, Queensland, has ruled out VAD legislation in the near term, but considerable pressure for legislative reform remains as the Victorian state precedent unfolds.²⁵ In August of 2018, a cross-party parliamentary committee in Western Australia (WA) recommended that the WA Government legalise voluntary euthanasia for patients suffering from a terminal illness, to be debated in 2019.^{26,27}

The Australian Victorian VAD Act delivers a thorough and highly specified set of eligibility criteria, procedures and safeguards.⁷ Eligibility to seek an assisted death requires that the patient be aged 18 years or older, have a legal capacity to make the request, be an Australian citizen and a resident of the state of Victoria for at least 12 months prior to making the request. Further criteria require that the patient:

- be ‘diagnosed with a disease, illness or medical condition’ and that is incurable; *and*
- is advanced, progressive and will cause death; *and*
- is expected to cause death within the next 6 months (although, if the disease is neurodegenerative, the life expectancy is 12 months or less); *and*

- is causing suffering to the individual which cannot be relieved in a manner that they consider tolerable.

A patient must be assessed as not suffering solely from a mental illness or a disability that is not terminal, and further, must make three separate written requests for assistance in dying and be assessed by (at least) two different medical practitioners. Medical assessors must also satisfy themselves that the applicant is ‘acting voluntarily and without coercion’. Only the patient that seeks assistance to die can ask for it, and if so granted, can change their mind at any time.

The Victorian VAD Act permits both patient self-administration of appropriately prescribed lethal substances as well as euthanasia. In the latter case, a consenting doctor may assist the patient in administering the lethal substances. Each process, (self-administration and euthanasia), is distinct and requires different administration permits (for substances) to be granted during the overall assessment processes.

With regards to prescribing, dispensing or disposing of VAD substances, the Act also specifies the information to be provided to the patient requesting voluntary assisted death by both the medicine prescriber and the dispensing pharmacist. Duties for the pharmacist cover aspects such as¹⁶:

- Provision of information and counselling for the patient regarding self-administration, handling and storage and the necessity of returning for disposal any dispensed VAD substance that was not self-administered. This latter role is to be undertaken by a declared ‘contact person’;
- Labelling requirements, such as the inclusion of the words “Warning: If ingested this substance will cause death”;
- Recording and notification procedures;
- Secure storage of lethal medicines after dispensing through the provision of a ‘locked-box’;

- Necessity of pharmacist organized disposal of returned/unused lethal medicines, and the recording of such disposal.

The Act also articulates that all potentially affected health practitioners may step away from the VAD processes should they hold conscientious objection.

The Victorian Implementation Taskforce is working through many issues pertinent to preparing for the practical implementation of the VAD Act. Of the myriad of briefs taken on by the Taskforce the development of the following are of particular importance for pharmacists and the pharmacy profession:

- Regulations to support the VAD Act;
- Best practice substances for use in voluntary assisted dying;
- Service delivery frameworks and models; and
- Education and training modules, such as communication skills.

At this pivotal time, it is pertinent that we undertake a mapping review of existing literature to explore experiences of pharmacists that perform these duties as part of their professional roles.

Method: A mapping review

Considerations regarding participation in any part of legalized practice to aid dying present serious moral, professional and ethical concerns for the health and other professions involved, including pharmacists.^{14,28} While most community discussion tends to focus upon physicians, patients and their loved ones, pharmacists also have an essential role and carry substantial responsibilities in assisted dying practices.^{13,14,29} A mapping review²⁰ of the literature was conducted for the period 1990 to 2019 so as to locate academic papers and reports relating to the involvement of pharmacists in some form of assisted dying.

A mapping review seeks to characterize the literature to identify types of studies, types of knowledge (i.e. epistemology), and consequent research gaps, from which

further primary research may be justified.²⁰ While a mapping review relies on systematic searching of the literature, the outcome-aim of this review type is to “map out and categorize existing literature on a particular topic”(p. 2).³⁰ Unlike other literature review methods such as a systematic review, a full appraisal and analysis of the contents of selected literature is not expected.^{20,30} As put by Cooper (2016, p. 76), “...published articles not only represent findings, but, indirectly, represent activity related to the finding.”³¹ In the case of this mapping review, contextualization of a research ‘scene’ (pharmacists’ and assisted dying) is presented, demonstrating both the presence and absence of certain types of studies.²⁰ The mapping review method thus provides an informed basis to consider whether research gaps exist and whether further research is justified.²⁰

To effect the search, relevant literature was identified through a systematic search of Medline, CINAHL (Cumulative Index to Nursing and Allied Health Literature) and IPA (International Pharmaceutical Abstracts) using the strategy (pharmacist OR pharmacists) AND (assisted death OR assisted suicide OR euthanasia OR aid in dying). In order to include literature from the countries where euthanasia or assisted dying is legal, searches included articles in English, French, and Dutch. The references and citations of studies initially uncovered were also searched (snowballing technique) to identify additional articles. An inclusive attitude was taken to selecting papers for analysis. The articles excluded were mainly opinion-based commentaries that did not include explanatory reasoning, balance and references.

Results and Discussion

The aim of this paper was to map the literature concerning pharmacy practice in the assisted dying domain. The table of studies (Table 1) categorizes each article according to both methodology and (where relevant), study design and summarizes the focus and findings of each study. Focus and findings reveal many important elements of

knowledge in the assisted dying domain (e.g. prevalent attitudes, views and perceptions). In contrast, methodology and design of each study reveal the ‘type of knowledge’ provided by the study and the participants from whom such knowledge arose. Importantly, the mapping review approach used in this study clarified an apparent research gap with respect to pharmacists’ actual experience with assisted death.

Figure 1 maps the 43 selected papers including commentaries, reports, a literature review and empirical studies. A more detailed summary of these publications is presented in Table 1.

Figure 1. The results of the mapping review of the literature relating to the involvement of pharmacists in some form of assisted dying.

231 **Table 1. Literature concerning pharmacy practice in the assisted dying domain, 1990 – 2019.** Presented in chronological order.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Ciesielski-Carlucci, C. ³²	1992	USA	Commentary		Medication use in euthanasia and ethical issues of concern.	The use of medications for euthanasia is discussed, with emphasis on ethical issues and implications for the pharmacist.
Vivian, J., Slaughter, R., and Calissi, P. ³³	1993	USA	Quantitative	Survey	Attitudes of Michigan pharmacists regarding medically assisted suicide.	Michigan pharmacists have similar views about the propriety of assisted suicide as compared to the general population in the state, with about half of the pharmacists disapproving of the practice in all circumstances and the other half indicating that there are some conditions that warrant participation in this activity.
Rupp, M. T., and Isenhower, H. L. ³⁴	1994	USA	Quantitative	Survey	Pharmacists' attitudes toward physician-assisted suicide.	While almost 70% of participants indicated support for physician assisted suicide, 66% expressed the opinion that it is inappropriate for physicians to involve pharmacists in the process without disclosure and consent; less than 40% indicated they would participate in the practice. Variability in opinions is influenced by personal experiences, religious conviction, and age.
van Wijmen, F. C. B., and Huinck-Mennen, W. H. T. ³⁵	1994	Netherlands	Commentary		An overview of the pharmacist's role in euthanasia.	Specific roles and duties of pharmacists are discussed including jurisdictional context and relevant developments in jurisprudence and regulation.
Rupp, M. T. ³⁶	1995	USA	Commentary		Moral and philosophical issues, assisted death and ethical codes, clinical issues.	Need for research to examine complex issues related to assisted death. Strategies are required to balance the needs of patients and health care providers that express conscientious objection.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Mullan, K., Allen, W. L., and Blushwood, D. B. ³⁷	1996	International	Commentary		To describe a legal structure for the accommodation of pharmacists' rights of conscience in the dispensing of drugs for pharmaceutically assisted death.	Need for pharmacy professional bodies to develop profession specific guidelines policies to safeguard the rights of pharmacists.
van Wijmen, F. C. B., and Huinck-Mennen, W. H. T. ³⁸	1996	Netherlands	Commentary		The role and responsibilities of pharmacists in decisions concerning euthanasia and assisted suicide, and the need for a new code of conduct.	The role and responsibilities of pharmacists are not given sufficient attention from either societal or professional viewpoints. A plea is made to formulate a new code of conduct regarding performing of medical decisions at the end of life.
Wagner, B. K. J. ³⁹	1996	USA	Commentary		Examines both abortion and assisted suicide, and then discusses the role of the pharmacy practitioner.	Personal views expressed that pharmacists' participation in both abortion and assisted suicide is ethically and morally incompatible with their professional oath. Suggests training for pharmacists to enable effective communication with those seeking service.
deBoer, A., Lau, H. S., and Porsius, A. ⁴⁰	1997	Netherlands	Quantitative	Survey	Survey of attitudes and practices with respect to euthanasia and physician-assisted suicide	The majority of participants expressed willingness to participate in physician-assisted suicide.
Onwuteaka-Philipsen, B. D., Muller, M. T., and van der Wal, G. ⁴¹	1997	Netherlands	Quantitative	Survey	Evaluation of a protocol to standardize euthanasia among pharmacists and general medical practitioners.	Both pharmacists and GPs had positive attitudes towards the importance and possibility of the standardisation of euthanatics. The majority of pharmacists and GPs were satisfied with the standard packages. This study shows that the implementation of standardised euthanatics was quite successful.
Slezak, M. ⁴²	1998	USA	Commentary		Informally gathered opinions of Oregon pharmacists regarding participation in new assisted suicide laws.	Article claims opinions are divided.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Woolfrey, J. ⁴³	1998	USA	Commentary		Guidance for practitioners, the uneasy role of hospice, the pharmacist's dilemma, implications for bioethics.	Lack of ongoing monitoring to assess both effectiveness and potential issues post implementation.
Schneiderhan, M. E. ⁴⁴	1999	USA	Commentary		Pharmacy practice and pharmacists' role, ethico-legal issues.	Suggests evaluating the complex interplay of variables that comprise the patient-doctor relationship to develop roadmap for guiding pharmacists' practice.
Veatch, R. M. ⁴⁵	1999	USA	Commentary		Review of published and grey literature focused on moral arguments between the rights of patents and of pharmacists on the basis of conscientious objection.	Emphasizes that pharmacists must rely on considerations involving conscience. Calls for strategies to assist pharmacists in reconciling their own position alongside the interests of the terminally ill.
Voss, D. ²⁹	1999	USA	Commentary		Actual assistance in dying is rendered by nurses, pharmacists, and respiratory technicians who are not included in the decision-making group. This involvement can place them in a contradictory locus between the necessity to act as independent professional and the expectation to obediently comply with the authority of medical practitioners.	The potential contradiction may lead many health care providers to remain silent on the subject of assisted death, diminishing their professionalism and their contribution to public argument.
Yung, D. K., and Whelan, A. M. ⁴⁶	1999	Canada	Quantitative	Survey	The attitudes of pharmacy students and pharmacists towards the role of the pharmacy profession and prescription drugs in assisted suicide were measured and compared.	Many students and pharmacists believed that prescription drugs are an appropriate means to accomplish physician-assisted suicide. Students were more unsure about the appropriateness of licensing bodies setting policies against pharmaceutically assisted suicide. Student and pharmacist respondents with a high level of religious conviction were more critical towards assisted suicide.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Hanlon, T. R. G., Weiss, M. C., and Rees, J. ⁴⁷	2000	UK	Quantitative	Survey	To explore British community pharmacists' views on assisted-suicide, including professional responsibility personal beliefs, and ethico-legal issues	Approximately 90% expressed a wish for inclusion of PAS in a code of ethics that provides guidelines for conscientious objectors. Concern raised regarding that approximately 30% of participants did not want to know the purpose of PAS prescription. This is believed contrary to pharmacists' professional obligations.
Lau, H. S., Riezebos, J., Abas, V., Porsius, A. J., and deBoer, A. ⁴⁸	2000	Netherlands	Quantitative	Survey	To study the attitudes and practices of assisted-dying among pharmacists.	Majority indicated willingness to dispense drugs for euthanasia and PAS in accordance with guidelines.
Naafs, N. J. ⁴⁹	2001	Netherlands	Commentary		Situational description, evolving pharmacy practice, ethical codes and the use of guidelines.	Facilitating euthanasia seen as part of pharmacists' providing patient-centred care by supporting patients to alleviate pain and suffering.
Hackett, E., and Francis, S.-A. ⁵⁰	2003	England and Wales	Quantitative	Survey	Pharmacists views and experiences of PAS in relation to personal characteristics and work environment.	More than 60% respondents reported willingness to dispense medications for voluntary active euthanasia and PAS. A significant minority of pharmacists expressed the view that they did not want to be informed of the intended purpose.
Bilsen, J., Bauwens, M., Bernheim, J., Vander Stichele, R., and Deliens, L. ⁵¹	2005	Belgium	Quantitative	Survey	Pharmacist attitudes and opinions and considerations	Pharmacists willingness to dispense prescriptions for euthanasia contingent on being well informed by the physician alongside having clear practice guidelines developed by own professional organisation.
Blondeau, D., Roy, L., Dumont, S., Godin, G., and Martineau, I. ⁵²	2005	Canada - Quebec	Quantitative	2 x 2 experimental design	To study the influence of two independent variables on pharmacist and doctor attitudes toward sedation at the end of life. The variables were prognosis (long - short) and type of suffering (physical - existential).	The results indicate that the type of suffering influences professionals' attitudes to end-of-life sedation. Pharmacists were more in favour of drugs to sedate patients that exhibited physical pain when compared with psychological (existential) suffering.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Meek, C. ⁵³	2006	UK	Commentary		Commentary on pharmacy practice issues and brief review of other international jurisdictions: issues for pharmacists	Legalisation PAS /euthanasia may have a range of impacts on pharmacy practice and be contrary to the personal beliefs of some pharmacists.
Meek, C. ⁵⁴	2006	UK	Commentary		Commentary on pharmacy practice issues including objection, and the role of professional bodies.	Suggests pharmacists utilise opportunity to shape legislation, thereby influence practice rather than have legislation dictate practice.
Wicclair, M. R. ⁵⁵	2006	USA	Commentary		Examines the obligations of pharmacy licensees and pharmacists in the context of conscience-based objections to filling lawful prescriptions for certain types of medications.	It is argued that the health needs of patients and the professional obligations of pharmacists limit the extent to which pharmacists may refuse to assist patients that have lawful prescriptions for medically indicated drugs.
Fass, J., and Fass, A. ⁵⁶	2011	USA	Commentary		Discusses a range of issues and challenges: Patient eligibility, pharmacist counselling and drug information	Highlights the need for PAS / euthanasia to be incorporated at the curriculum level to adequately prepare pharmacists for their future practice needs.
Boissinot, L., Benamou, M., Léglise, P., Mancret, R., and Huchon-Bécel, D. ⁵⁷	2014	France	Commentary		Though not authorized at present in France, the role of the hospital pharmacist in medically assisted suicide is discussed. This article aims to propose practical thinking on the possible role of the hospital pharmacist in France.	Medically assisted suicide practices, if authorized by law, should remain exceptional, and the law strictly enforced. The pharmacist could be one of the "lawkeepers".
Oakman, B. N., Campbell, H. E., and Runk, L. M. ⁵⁸	2015	USA	Commentary		Moral and philosophical issues, ethical codes, clinical issues, and the influence of patient centered pharmaceutical care on pharmacists participating in actively ending patients' lives.	Argues that, in order to meet their professional obligations, pharmacists must be fully informed about the intended purpose of the medication that they are dispensing and highlight that in knowing, some will be conflicted between their professional and personal beliefs.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Berard, G., and Walker, J. ⁵⁹	2016	Canada	Commentary		Comments on protection of conscience and a range of issues and considerations	Identified concerns related to pharmacists' role in PAS including protection of conscience, providing counselling and drug information.
Varadarajan, R., Freeman, R. A., and Parmar, J. R. ⁶	2016	USA	Commentary		Current practices, medications used and statistics relating to prescription frequency and death rates from the participating States. Pharmacists' roles and ethico-legal issues.	Identified need for legal provisions for participating and non-participating pharmacist.
Cobaugh, D. J. ⁶⁰	2017	USA	Commentary		Pharmacist participation in medical aid in dying	The American Society of Health-System Pharmacists initiated development of policy to safeguard pharmacists' rights to participate/decline participation in PAS including a legislative summary of when PAS is permitted.
Hughes, M. T. ²⁸	2017	USA	Commentary		Issues that pharmacists should consider as they formulate their opinions about policy implications and individual practice.	Highlights the need for pharmacists to carefully consider their position when deciding to participate or to recuse themselves from practice in assisted death.
Li, M., Watt, S., Escaf, M., Gardam, M., Heesters, A., O'Leary, G., and Rodin, G. ¹³	2017	Canada	Report		Synopsis of hospital MAiD implementation (including pharmacy) at University Health Network (UHN) Toronto, Ontario	Advocate for the inclusion of PAS for students of the health and allied health professions and students of social support services.
Buijsen, M. ⁶¹	2018	Netherlands	Commentary		Doctor – Pharmacist relationship	Highlights that in addition to a lack of awareness among doctors that dispensing drugs for the purpose of PAS is not a normal daily activity for pharmacists, there is also lack of clarity surrounding the rights of pharmacists to exercise conscientious objection.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
Fujioka, J. K., Mirza, R. M., McDonald, P. L., and Klinger, C. A. ¹⁴	2018	International	Literature review	Scoping review	Health professionals: roles and challenges in relation to MAiD.	Highlights the need for clear guidelines and protocols that define each profession's role, scope of practice and legal boundaries for MAiD.
Harty, C., Chaput, A., Buna, D., Trouton, K., and Naik, V. ⁶²	2018	Canada	Report		To outline best practices for the safe dispensing, administration, and evaluation of the plausibility of an oral MAiD provision.	Compares oral and intravenous administered drugs in terms of time to death. Provides feedback from family regarding experience.
Isaac, S., Chaar, B., and Savulescu, J. ⁶³	2018	Canada	Commentary		Point, counterpoint, on pharmacists' conscientious objection to supply medications for MAiD.	Suggests one way to safeguard the care for patients seeking PAS is to limit admission for medical and pharmacy students to only those that do not object.
Kruijtbosch, M., Göttgens-Jansen, W., Floor-Schreuderling, A., van Leeuwen, E., and Bouvy, M. L. ⁶⁴	2018	Netherlands	Qualitative	Qualitative content analysis	Thematic qualitative content analysis of moral dilemmas described in narratives written by Dutch pharmacists.	Found a diverse range of moral dilemmas experienced by community pharmacists related to autonomy in PAS. Twenty-two themes were identified including end-of-life pharmaceutical care associated with challenges to pharmacists' expertise and autonomy.
Murphy, A. L., O'Reilly, C., Martin-Misener, R., Ataya, R., and Gardner, D. ⁶⁵	2018	Canada	Quantitative	Survey	Community pharmacists' attitudes on suicide	Pharmacist need further education for supporting patients that wish to engage in PAS as within the traditional community pharmacy context, pharmacists do not normally encounter this patient group.
Rupp, M. T. ⁶⁶	2018	USA	Commentary		The fact of death and the notion of good-death.	Rejects the notion that participation in PAS is in violation of professional oath.
Traynor, K. ⁶⁷	2018	USA	Commentary		Colorado MAiD numbers	Outlines policy that affirms pharmacists' right to participate or recuse themselves.
Verweel, L., Rosenberg-Yunger, Z. R., Movahedi, T., and Malek, A. H. ⁶⁸	2018	Canada	Mixed Methods	Thematic document analysis and survey	Thematic document analysis of pharmacy guidelines, position statements and standards of practice from pharmacy regulatory authorities across Canada, and survey of	Need for development of educational resources to support pharmacists with their practice needs in light of changing practice landscape and extended scope of practice.

Author(s)	Publication Year	Jurisdiction of Focus	Publication Style or Methodology	Design	Article Focus	Results/Findings/Outcomes
					pharmacists, students about their perceptions of MAiD.	
Gallagher, A., Gould, O., LeBlanc, M., Manual, L., Brideau-Laughlin, D. ⁶⁹	2019	Canada	Quantitative	Survey	Survey the knowledge and attitudes of hospital pharmacy staff in Canada regarding MAiD and to determine the factors that might influence those opinions.	Most respondents supportive of MAiD. Nearly all respondents reported lacking comprehensive education on the topic. Influential factors on opinions included strong religious beliefs, region and knowledge of legislation.

Study design

Of the 43 selected papers, 26 articles were commentaries including editorials, opinion pieces and descriptive discussions. Fourteen were empirical studies. The remaining 3 comprised: 1 scoping literature review¹⁴ and 2 published reports.^{13,62} Of the 14 empirical studies, 12 studies were designed around surveys. One article involving a survey of pharmacist perceptions of medically assisted dying practice by Verweel et al.⁶⁸ also included a thematic document analysis of pharmacy guidelines, position statements and standards of practice from pharmacy regulatory authorities across Canada.

Two of the 14 empirical studies did not involve survey design. The article by Kruijtbosch et al.⁶⁴ involved thematic analysis of pharmacists' narratives concerning perceived moral dilemmas in practice. Another article by Blondeau et al.⁵², used a 2 x 2 experimental design examining the influence of two independent variables on pharmacists' attitudes toward sedation at the end of life. The articles by Verweel et al. and Kruijtbosch et al. represent the only studies in the summary that utilized a qualitative research approach in the methodology.

Type of knowledge

Of the 43 studies identified, the 26 commentaries provided knowledge through shared 'conjecture' or opinion. Most commentaries centered on pharmacist roles, ethico-legal and moral challenges and educational concerns in relation to participation, or non-participation. The main issues of concern related to ethico-legal concerns and particularly conscientious consideration and objection.^{28,29,36,37,43-45,53,56,57,60,61,63,70} Other than interpreting pharmacist roles in relation to relevant legislation and regulations, some commentaries addressed the contextualization of the principles of pharmaceutical care⁷¹, with the idea of assisting patients to die in certain circumstances.^{44,49}

Clearly, the controversial nature of assisted dying has been very motivating for authors to share their views, concerns and advice in commentary. As helpful and insightful as the commentaries may be for thinking through potential issues relating to assisted dying practice, realistically, commentaries can only serve to inform the anticipating practitioner from a theoretical distance. Perhaps such theory is helpful for the initial contemplative stages for pharmacists: whether to opt-in or opt-out of this type of practice participation from the beginning. The commentaries were unable to inform us of how pharmacists that had not sought conscientious objection actually experienced their practice in this area. Lived experience ‘on-the-ground’ so to speak, is more rich and complex than theoretical summaries, no matter how carefully those summaries are constructed.⁷²

Twelve of the 14 empirical publications were quantitative survey studies that mainly focused on some aspect of pharmacists’ attitudes, views, and opinions concerning assisted dying. These attitude or sentiment measurements were undertaken through the period 1993 to 2019 and from a range of nations: 4 from Canada, 3 from the Netherlands, 2 from each of the UK and the USA, and 1 from Belgium. All but 2 of the survey studies explored attitudes of pharmacists *without differentiating* between those with *actual experience* of professional participation in lawfully sanctioned assisted death, from those without such experience. Nor did the 2 empirical studies (by Kruijtbosch et al.⁶⁴ and Blondeau et al.⁵²) that did *not* use a survey design specifically focus on participants actually practicing in assisted dying. The lack of differentiation delivered knowledge elements (attitudes, views and opinions), that were not necessarily grounded in actual experience.

Of the 2 survey exceptions that studied pharmacists actually involved in assisted dying pharmacy practice, 1 was the study by Lau et al..⁴⁸ This study from the Netherlands collected data from pharmacists who had received *explicit* requests from

physicians to dispense drugs for euthanasia or physician-assisted suicide. The researchers collected data relating to participants' concordance of fulfilling requests with process-guidelines that were published by the Royal Dutch Pharmaceutical Association. The other exception was a study by Onwuteaka-Philipsen et al.⁴¹ that was also based in the Netherlands. The study evaluated the implementation of a protocol to standardize euthanasia processes among pharmacists and general medical practitioners. While these two studies selected practitioner-respondents specifically practicing in the assisted dying domain, the foci of the studies were on concordance with process guidelines and evaluation of a standardization process, respectively. Neither study addressed aspects of the day-to-day lived experience of involved practitioners.

A recent study from Canada highlighted many areas of complexity and uncertainty that need to be foregrounded and addressed. Verweel et al.⁶⁸ pointed out that Canadian pharmacists' roles in medical assistance in dying are complex, and in many instances, roles lack clarity. Uncertainties were situated around how to reconcile practice standards with moral convictions, while at the same time "maintaining collaborative relationships with their patients" (p. 128). The analysis of survey responses by Verweel et al. also highlighted concerns regarding the potential for the experience of moral and professional distress through participation.⁶⁸ Their document analysis of published Canadian guidelines revealed the absence of any reference to the emotional impact- that pharmacists may experience, or to coping strategies that pharmacists might use in the event of experienced emotional distress. They concluded that there was a need for relevant professional development, especially regarding "communication" and "cop(ing) with negative emotions associated with MAiD" (p. 129). Such needs underscore the necessity of illuminating what is truly important, relevant and required, from pharmacists already participating in assisted dying practice.

Research Gap

The mapping review of the literature 1990-2019 drew attention to the change in pharmacists' roles in the assisted dying domain with respect to the moral and ethical tensions associated with this change,^{32,36,39,43-45,53,59,64,66} the importance of conscious objection and the rights of professionals,^{28,60,67} efficacy of medication protocols, and the contribution of guidelines and procedures,⁶² as well as the contribution of guidelines and protocols in defining and performing the role.^{14,37,41,48} The literature highlighted a need for education to prepare pharmacists for this role^{68,69} including resources for practice and continuing professional development,^{65,68} entry to practice curriculum⁵⁶ and potential changes to pharmacy program admission policies to recruit individuals who are fully aware of pharmacists' changing roles in this domain.⁶³ More recent research highlighted issues related to pharmacists' practice in assisted dying such as perceiving a lack of knowledge of MAiD processes, as well as collaboration and changing relationships with physicians.^{61,68} However there is little published about the lived experiences of pharmacists actually involved in assisted dying. This reveals an epistemological gap in existing knowledge in that the lived experiences of practitioners actually involved in assisted dying are both under-researched from an appropriate philosophical perspective. Authors have noted that the paucity of research may be because it is difficult for pharmacists to give voice to those experiences.²⁹

There are many participating practitioners in the worldwide pharmacy profession that could meaningfully contribute to studies designed to illuminate actual pharmacy practice experiences in the domain of assisted dying. It is time for researchers to lend a hand in capturing these stories and developing a deeper understanding of assisting patients with their own death. Practitioners, policy makers, patients and those calling for education^{65,68,69} would then have something grounded and tangible to guide them.

Limitations

Time constraints generally impact the product of mapping reviews since their execution is connected to and contextualized by the development of a broader research goal that the mapping review is designed to inform.²⁰ The studies reported and mapped in this paper have been presented through broad description, focusing mainly on conclusions that can be drawn from examining study methodology and design, rather than analysis of detailed content. Despite the demonstration of gaps in extant research methodology and design, the mapping review is also necessarily less sophisticated and less thorough than the more common systematic review.²⁰ The mapping review presented here can also serve as an invitation for a more in-depth analysis of the detailed content of the selected papers (e.g. through the systematic review methodology²⁰), that have been published over a 27 year period.

Future research

The identified absence of studies utilizing qualitative methodology to explore the lived experience of pharmacists actually practicing in the domain of assisted dying is important. Such a deficit serves as a motivation to fill the gap. Doing so through planned future research will add a different type of knowledge, beyond the factual and more objectified content of statutes, regulations, policies, procedures and the surveyed opinions and perceptions that surround them. Indeed, exploration of the authentic lived experience of current practitioners from different jurisdictions, but within the same international professional pharmacy-family promises to deliver a deeper and more meaningful understanding of a controversial and potentially problematic practice domain.

The next research steps planned by the authors of this study aim to address the knowledge gap through a multi-phase international study. The overall aim of the multi-phase study is to build a more detailed and educationally useful understanding of the

lived experiences of pharmacists that are actually involved in assisted dying practice in jurisdictions where assisted dying is permitted. The next phase, currently underway, is to develop an exploratory framework as a guide to inquire about the lived experiences of pharmacists participating in assisted dying practice. The subsequent research phase will apply this framework to first explore the actual experiences of Canadian pharmacists practicing in the MAiD domain, then extend to include practice experiences of pharmacists in jurisdictions of northwest Europe.

Conclusion

The aim of this study was to characterize extant studies according to their theoretical perspective by observation of study design, as well as identify gaps in the evidence base and to provide a transparent and organized summary of literature from which further research decisions can be made. In the mapping review of 43 publications, a significant epistemological gap in the literature was identified with respect to empirical research exploring the lived experiences of pharmacists *actually* engaged in the legitimate practice of caring for patients that seek assisted death. Knowledge of pharmacy practice in medically assisted dying, from the viewpoint of the experienced practitioner, is unavailable. Publications to date offer commentary, sentiment measurements and studies into compliance with procedures and protocols. With lawful assisted dying procedures being actively considered by an expanding number of international jurisdictions, pharmacist practitioners, policy makers, patients and educators would be well served by research illuminating pharmacists' authentic practice experiences in the domain of assisted dying. Continuing research along these lines was described.

Acknowledgements

The authors wish to acknowledge and thank the XXXX, within the School of XXXX, for supporting the international collaboration represented by this authorship team.

387 **Funding**

388 This research did not receive any specific grant from funding agencies in the public,
389 commercial, or not-for-profit sectors.

390

ACCEPTED MANUSCRIPT

References

1. Mossialos E, Djordjevic A, Osborn R, Sarnak D, eds. *International Profiles of Health Care Systems*. New York, USA: The Commonwealth Fund; 2017.
2. Marriott JL. What can be done to help the pharmacy profession advance globally? *Am J Pharm Educ*. 2018;82:908-909.
3. Schindel TJ, Yuksel N, Breault R, Daniels J, Varnhagen S, Hughes CA. Perceptions of pharmacists' roles in the era of expanding scopes of practice. *Res Soc Adm Pharm*. 2017;13:148-161.
4. Mossialos E, Courtin E, Naci H, et al. From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management. *Health Policy*. 2015;119:628-639.
5. Babar ZU-D, Scahill S, Nagaria RA, Curley LE. The future of pharmacy practice research – Perspectives of academics and practitioners from Australia, NZ, United Kingdom, Canada and USA. *Res Soc Adm Pharm*. 2018;14:1163-1171.
6. Varadarajan R, Freeman RA, Parmar JR. Aid-in-dying practice in Europe and the United States: Legal and ethical perspectives for pharmacy. *Res Soc Adm Pharm*. 2016;12:1016-1025.
7. Voluntary Assisted Dying Act 2017, No. 61 of 2017.
[http://www.legislation.vic.gov.au/Domino/Web_Notes/LDMS/PubStatbook.nsf/f932b66241ecf1b7ca256e92000e23be/B320E209775D253CCA2581ED00114C60/\\$FILE/17-061aa%20authorised.pdf](http://www.legislation.vic.gov.au/Domino/Web_Notes/LDMS/PubStatbook.nsf/f932b66241ecf1b7ca256e92000e23be/B320E209775D253CCA2581ED00114C60/$FILE/17-061aa%20authorised.pdf) ; 2017 Accessed 31.08.18.
8. Emanuel EJ, Onwuteaka-Philipsen BD, Urwin JW, Cohen J. Attitudes and practices of euthanasia and physician-assisted suicide in the United States, Canada, and Europe. *JAMA*. 2016;316:79-90.
9. Martin SS. Assisted Dying in Victoria – Part I: An overview of the Voluntary Assisted Dying Act 2017 (Vic). *ILA Reporter*. Online: International Law Association (Australian Branch); 2017.
<http://ilareporter.org.au/2018/04/assisted-dying-in-victoria-part-i-an-overview-of-the-voluntary-assisted-dying-act-2017-vic-steve-s-martin/> Accessed 31.08.18.
10. Ziegler SJ. Collaborated death: An exploration of the Swiss model of assisted suicide for its potential to enhance oversight and demedicalize the dying process. *J LawMed Ethics*. 2009;37:318-330.

- 424 **11.** Hurst SA, Mauron A. Assisted suicide and euthanasia in Switzerland: Allowing
425 a role for non-physicians. *BMJ*. 2003;326:271-273.
- 426 **12.** Downie J. Medical Assistance in Dying: Lessons for Australia from Canada.
427 *QUT Law Review*. 2017;17:127-146.
- 428 **13.** Li M, Watt S, Escaf M, et al. Medical assistance in dying – Implementing a
429 hospital-based program in Canada. *New Engl J Med*. 2017;376:2082-2088.
- 430 **14.** Fujioka JK, Mirza RM, McDonald PL, Klinger CA. Implementation of medical
431 assistance in dying (MAiD): A scoping review of health care providers’
432 perspectives. *J. Pain Symptom Manage*. 2018;55:1564-1576.
- 433 **15.** State Government of Victoria. *Ministerial Advisory Panel on Voluntary Assisted*
434 *Dying: Final Report*. Melbourne, Victoria: Department of Health & Human
435 Services;2017.
436 [https://www2.health.vic.gov.au/about/publications/researchandreports/ministeria](https://www2.health.vic.gov.au/about/publications/researchandreports/ministerial-advisory-panel-on-voluntary-assisted-dying-final-report)
437 [l-advisory-panel-on-voluntary-assisted-dying-final-report](https://www2.health.vic.gov.au/about/publications/researchandreports/ministerial-advisory-panel-on-voluntary-assisted-dying-final-report) Accessed 31.08.18.
- 438 **16.** Voluntary Assisted Dying Regulations 2018. S.R. No. 142/2018.
439 [http://www.legislation.vic.gov.au/Domino/Web_Notes/LDMS/PubStatbook.nsf/](http://www.legislation.vic.gov.au/Domino/Web_Notes/LDMS/PubStatbook.nsf/93eb987ebadd283dca256e92000e4069/D550921996E9F89BCA258313001B4FE5/%24FILE/18-142sra%20authorised.pdf)
440 [93eb987ebadd283dca256e92000e4069/D550921996E9F89BCA258313001B4F](http://www.legislation.vic.gov.au/Domino/Web_Notes/LDMS/PubStatbook.nsf/93eb987ebadd283dca256e92000e4069/D550921996E9F89BCA258313001B4FE5/%24FILE/18-142sra%20authorised.pdf)
441 [E5/%24FILE/18-142sra%20authorised.pdf](http://www.legislation.vic.gov.au/Domino/Web_Notes/LDMS/PubStatbook.nsf/93eb987ebadd283dca256e92000e4069/D550921996E9F89BCA258313001B4FE5/%24FILE/18-142sra%20authorised.pdf) Accessed 30.11.18.
- 442 **17.** McMaugh J. Member opinion: Voluntary assisted dying: The role of
443 pharmacists in new euthanasia laws. *Australian Pharmacist*. 2018;37:15.
- 444 **18.** State Government of Victoria. *Implementation Taskforce - Voluntary Assisted*
445 *Dying: Terms of Reference*. Online: State Government of Victoria; 2017.
446 [https://www2.health.vic.gov.au/about/publications/factsheets/vad-](https://www2.health.vic.gov.au/about/publications/factsheets/vad-implementation-taskforce-terms-of-reference)
447 [implementation-taskforce-terms-of-reference](https://www2.health.vic.gov.au/about/publications/factsheets/vad-implementation-taskforce-terms-of-reference) Accessed 31.08.18.
- 448 **19.** State Government of Victoria. Implementation Taskforce projects. 2018;
449 [https://www2.health.vic.gov.au/hospitals-and-health-services/patient-care/end-](https://www2.health.vic.gov.au/hospitals-and-health-services/patient-care/end-of-life-care/voluntary-assisted-dying/implementation-taskforce-projects)
450 [of-life-care/voluntary-assisted-dying/implementation-taskforce-projects](https://www2.health.vic.gov.au/hospitals-and-health-services/patient-care/end-of-life-care/voluntary-assisted-dying/implementation-taskforce-projects)
451 Accessed 03.10.18.
- 452 **20.** Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and
453 associated methodologies. *Health InfoLibr J*. 2009;26:91-108.
- 454 **21.** Fitzgerald R. Baby boomers will not lie down and die an undignified death. *The*
455 *Sydney Morning Herald*. December 8, 2016.
- 456 **22.** ABC-NEWS. Euthanasia debate: NSW Parliament rejects bill on voluntary
457 assisted dying. *ABC News*. 2017. [http://www.abc.net.au/news/2017-11-16/nsw-](http://www.abc.net.au/news/2017-11-16/nsw-parliament-votes-on-euthanasia-bill/9158384)
458 [parliament-votes-on-euthanasia-bill/9158384](http://www.abc.net.au/news/2017-11-16/nsw-parliament-votes-on-euthanasia-bill/9158384) Accessed 09.08.18.

23. ABC-NEWS. Voluntary euthanasia: South Australian Parliament knocks back Death With Dignity euthanasia bill. *ABC News*. 2017.
<http://www.abc.net.au/news/2016-11-16/voluntary-euthanasia-debate-in-south-australia-goes-to-committee/8031776> Accessed 31.08.18.
24. ABC News. Tasmania votes down voluntary euthanasia bill for third time in 10 years. *ABC News*. 2017. <http://www.abc.net.au/news/2017-05-24/tasmania-votes-down-euthanasia-bill/8555882> Accessed 15.10.18.
25. Elks S. Annastacia Palaszczuk rails against Queensland euthanasia push. *The Australian*. January 23, 2018.
26. Atlay K. Voluntary assisted dying wins parliamentary backing in WA. *Australian Doctor*. Online: 2018.
<https://www.australiandoctor.com.au/news/voluntary-assisted-dying-wins-parliamentary-backing-wa>; Accessed 31.08.18.
27. ABC News. Voluntary euthanasia should be legalised in WA to end 'unnecessary suffering', report finds. 2018. <http://www.abc.net.au/news/2018-08-23/voluntary-euthanasia-should-be-legalised-in-wa-report-finds/10155910>; Accessed 15.10.18.
28. Hughes MT. The pharmacist and medical aid in dying. *Am J Health Syst Pharm*. 2017;74:1253-1260.
29. Voss D. Ethical care and health care professionals' involvement in physician-assisted suicide. *J Pharm Care in Pain Sympt Control*. 1999;7:43-52.
30. O'Cathain A, Thomas K, Drabble S, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. *BMJ Open*. 2013;3:e002889.
31. Cooper ID. What is a "mapping study?". *J Med Lib Assoc: JMLA*. 2016;104:76.
32. Ciesielski-Carlucci C. Critical implications and ethical considerations of the pharmacologic methods used in euthanasia. *Calif J Hosp Pharm*. 1992;4:18.
33. Vivian J, Slaughter R, Calissi P. Michigan pharmacists' attitudes about medically-assisted suicide. *J Mich Pharm*. 1993;31:490-493.
34. Rupp MT, Isenhower HL. Pharmacists' attitudes toward physician-assisted suicide. *Am J Health Syst Pharm*. 1994;51:69-74.
35. van Wijmen FCB, Huinck-Mennen WHT. Apotheker en euthanasie [Pharmacist and euthanasia]. *Pharm Weekbl*. 1994;129:324-329.
36. Rupp MT. Issues for pharmacists in assisted patient death. *J Pharm Care in Pain Sympt Control*. 1995;3:43-53.

- 494 **37.** Mullan K, Allen WL, Blushwood DB. Conscientious objection to assisted death:
 495 Can pharmacy address this in a systematic fashion? *Ann Pharmacother.*
 496 1996;30:1185-1191.
- 497 **38.** van Wijmen FCB, Huinck-Mennen WHT. De apotheker en medische
 498 beslissingen rond het levenseinde. Een pleidooi voor een gedragscode voor
 499 apothekers [Pharmacist and medical decisions at the end of life: plea for a code
 500 of conduct for pharmacists]. *Pharm Weekbl.* 1996;131:46-51.
- 501 **39.** Wagner BKJ. Pharmacists should not participate in abortion or assisted suicide.
 502 *Ann Pharmacother.* 1996;30:1192-1196.
- 503 **40.** deBoer A, Lau HS, Porsius A. Physician-assisted death and pharmacy practice
 504 in the Netherlands. *New Engl J Med.* 1997;337:1091-1092.
- 505 **41.** Onwuteaka-Philipsen BD, Muller MT, van der Wal G. Euthanatics:
 506 Implementation of a protocol to standardise euthanatics among pharmacists and
 507 GPs. *Patient Educ Couns.* 1997;31:131-137.
- 508 **42.** Slezak M. Suicide law divides Oregon R.Ph.s. *American Druggist.* 1998;215:11.
- 509 **43.** Woolfrey J. What Happens Now?: Oregon and physician-assisted suicide.
 510 *Hastings Cent Rep.* 1998;28:9-17.
- 511 **44.** Schneiderhan ME. Physician-assisted suicide and euthanasia: The pharmacist's
 512 perspective. *Omega-J Death Dying.* 1999;40:89-99.
- 513 **45.** Veatch RM. The pharmacist and assisted suicide. *Am J Health Syst Pharm.*
 514 1999;56:260-266.
- 515 **46.** Yung DK, Whelan AM. Attitudes of pharmacy students and pharmacists
 516 towards assisted suicide. *Can J Hosp Pharm.* 1999;52:227-233.
- 517 **47.** Hanlon TRG, Weiss MC, Rees J. British community pharmacists' views of
 518 physician-assisted suicide (PAS). *J Med Ethics.* 2000;26:363-369.
- 519 **48.** Lau HS, Riezebos J, Abas V, Porsius AJ, De Boer A. A nation-wide study on
 520 the practice of euthanasia and physician-assisted suicide in community and
 521 hospital pharmacies in the Netherlands. *Pharm World Sci.* 2000;22:3-9.
- 522 **49.** Naafs NJ. Pharmaceutical care until the end: The role of pharmacists in
 523 euthanasia in the Netherlands. *Pharm World Sci.* 2001;23:129-131.
- 524 **50.** Hackett E, Francis S-A. "Death was a blessing" – Should it ever be
 525 pharmaceutically hastened? British pharmacists' views. *Pharm World Sci.*
 526 2003;25:288-293.

51. Bilsen J, Bauwens M, Bernheim J, Vander Stichele R, Deliëns L. Physician-assisted death: Attitudes and practices of community pharmacists in East Flanders, Belgium. *Palliat Med.* 2005;19:151-157.
52. Blondeau D, Roy L, Dumont S, Godin G, Martineau I. Physicians' and pharmacists' attitudes toward the use of sedation at the end of life: Influence of prognosis and type of suffering. *J Palliat Care.* 2005;21:238.
53. Meek C. Pharmacy involvement where assisted suicide and euthanasia are permitted. *Pharm J.* 2006;277:614-615.
54. Meek C. Pharmacy and assisted suicide: What can be learnt from experience abroad? *Pharm J.* 2006;277:639-640.
55. Wicclair MR. Pharmacies, pharmacists, and conscientious objection. *Kennedy Inst Ethics J.* 2006;16:225-250.
56. Fass J, Fass A. Physician-assisted suicide: Ongoing challenges for pharmacists. *Am J Health Syst Pharm.* 2011;68:846-849.
57. Boissinot L, Benamou M, Légère P, Manciet R, Huchon-Bécel D. Euthanasie et/ou suicide médicalement assisté: Réflexion sur la nouvelle responsabilité du pharmacien hospitalier [Euthanasia and/or medically assisted suicide: Reflection on the new responsibility of the hospital pharmacist]. *Annales pharmaceutiques françaises [French Pharmaceutical Annals].* 2014;72:82-89.
58. Oakman BN, Campbell HE, Runk LM. Death with dignity: The developing debate among health care professionals. *Consul Pharm.* 2015;30:352-355.
59. Berard G, Walker J. CPhA surveys pharmacists on physician-assisted dying. *Can Pharm J.* 2016;149:54-55.
60. Coughlin DJ. Medical aid in dying. *Am J Health Syst Pharm.* 2017;74:1214-1215.
61. Buijsen MA. Discuss the relationship between physicians and pharmacists in the context of euthanasia. *Ned Tijdschr Geneesk.* 2018;162:D2049-D2049.
62. The Canadian Association of MAiD Assessors and Providers. The oral MAiD option in Canada. Part 2: Processes for providing review and recommendations; 2018. <https://camapcanada.ca/wp-content/uploads/2019/01/OralMAiD-Process.pdf> Accessed: 13.05.19.
63. Isaac S, Charr B, Savulescu J. Should pharmacists be allowed to conscientiously object to medicines supply on the basis of their personal beliefs? *Can J Hosp Pharm.* 2018;71:149-151.

- 561 **64.** Kruijtbosch M, Göttgens-Jansen W, Floor-Schreudering A, van Leeuwen E,
562 Bouvy ML. Moral dilemmas of community pharmacists: a narrative study. *Int J*
563 *Clin Pharm*. 2018;40:74-83.
- 564 **65.** Murphy AL, O'Reilly C, Martin-Misener R, Ataya R, Gardner D. Community
565 pharmacists' attitudes on suicide: A preliminary analysis with implications for
566 medical assistance in dying. *Can Pharm J*. 2018;151:17-23.
- 567 **66.** Rupp MT. Dying better. *J Am Pharm Assoc*. 2018;58:250-252.
- 568 **67.** Traynor K. Reports offer window on medical aid in dying. *Am J Health Syst*
569 *Pharm*. 2018;75:413-414.
- 570 **68.** Verweel L, Rosenberg-Yunger ZR, Movahedi T, Malek AH. Medical assistance
571 in dying: Examining Canadian pharmacy perspectives using a mixed-methods
572 approach. *Can Pharm J*. 2018;151:121-132.
- 573 **69.** Gallagher A, Gould O, LeBlanc M, Manuel L, Brideau-Laughlin D. Knowledge
574 and attitudes of hospital pharmacy staff in Canada regarding medical assistance
575 in dying (MAiD). *Can J Hosp Pharm*. 2019;72.
- 576 **70.** Varadarajan R, Freeman RA, Parmar JR. Aid-in-dying practice in the United
577 States: Legal and ethical perspectives for pharmacy. *Res Soc Adm Pharm*.
578 2016;12:e17.
- 579 **71.** Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical
580 care. *Am J Hosp Pharm* 1990;47:533-543.
- 581 **72.** Sandberg J, Tsoukas H. Grasping the logic of practice: Theorizing through
582 practical rationality. *Acad Manage Rev*. 2011;36:338-360.